6.5.1) PREVENTION OF ABSORPTION/PREHOSPITAL
A) ACTIVATED CHARCOAL 1) Activated charcoal adsorbs sympathomimetics and opioids effectively. 2) PREHOSPITAL ACTIVATED CHARCOAL ADMINISTRATION a) Consider prehospital administration of activated charcoal as an aqueous slurry in patients with a potentially toxic ingestion who are awake and able to protect their airway. Activated charcoal is most effective when administered within one hour of ingestion. Administration in the prehospital setting has the potential to significantly decrease the time from toxin ingestion to activated charcoal administration, although it has not been shown to affect outcome (Alaspaa et al, 2005; Thakore & Murphy, 2002; Spiller & Rogers, 2002). 1) In patients who are at risk for the abrupt onset of seizures or mental status depression, activated charcoal should not be administered in the prehospital setting, due to the risk of aspiration in the event of spontaneous emesis. 2) The addition of flavoring agents (cola drinks, chocolate milk, cherry syrup) to activated charcoal improves the palatability for children and may facilitate successful administration (Guenther Skokan et al, 2001; Dagnone et al, 2002).
3) CHARCOAL DOSE a) Use a minimum of 240 milliliters of water per 30 grams charcoal (FDA, 1985). Optimum dose not established; usual dose is 25 to 100 grams in adults and adolescents; 25 to 50 grams in children aged 1 to 12 years (or 0.5 to 1 gram/kilogram body weight) ; and 0.5 to 1 gram/kilogram in infants up to 1 year old (Chyka et al, 2005). 1) Routine use of a cathartic with activated charcoal is NOT recommended as there is no evidence that cathartics reduce drug absorption and cathartics are known to cause adverse effects such as nausea, vomiting, abdominal cramps, electrolyte imbalances and occasionally hypotension (None Listed, 2004).
b) ADVERSE EFFECTS/CONTRAINDICATIONS 1) Complications: emesis, aspiration (Chyka et al, 2005). Aspiration may be complicated by acute respiratory failure, ARDS, bronchiolitis obliterans or chronic lung disease (Golej et al, 2001; Graff et al, 2002; Pollack et al, 1981; Harris & Filandrinos, 1993; Elliot et al, 1989; Rau et al, 1988; Golej et al, 2001; Graff et al, 2002). Refer to the ACTIVATED CHARCOAL/TREATMENT management for further information. 2) Contraindications: unprotected airway (increases risk/severity of aspiration) , nonfunctioning gastrointestinal tract, uncontrolled vomiting, and ingestion of most hydrocarbons (Chyka et al, 2005).
6.5.2) PREVENTION OF ABSORPTION
A) ACTIVATED CHARCOAL 1) Activated charcoal may adsorb cocaine leaking or leaching from cocaine packets, as well as serve as a marker for GI transit. It has been suggested that some packets are semipermeable and do not need to rupture to cause death from cocaine toxicity (Queen & Glauser, 2002; Wetli & Mittleman, 1981). 2) Although activated charcoal has been used in body packers, its spillage into the peritoneum secondary to perforation of the bowel wall or during surgery is of concern (Olmedo et al, 2001). 3) CHARCOAL ADMINISTRATION a) Consider administration of activated charcoal after a potentially toxic ingestion (Chyka et al, 2005). Administer charcoal as an aqueous slurry; most effective when administered within one hour of ingestion.
4) CHARCOAL DOSE a) Use a minimum of 240 milliliters of water per 30 grams charcoal (FDA, 1985). Optimum dose not established; usual dose is 25 to 100 grams in adults and adolescents; 25 to 50 grams in children aged 1 to 12 years (or 0.5 to 1 gram/kilogram body weight) ; and 0.5 to 1 gram/kilogram in infants up to 1 year old (Chyka et al, 2005). 1) Routine use of a cathartic with activated charcoal is NOT recommended as there is no evidence that cathartics reduce drug absorption and cathartics are known to cause adverse effects such as nausea, vomiting, abdominal cramps, electrolyte imbalances and occasionally hypotension (None Listed, 2004).
b) ADVERSE EFFECTS/CONTRAINDICATIONS 1) Complications: emesis, aspiration (Chyka et al, 2005). Aspiration may be complicated by acute respiratory failure, ARDS, bronchiolitis obliterans or chronic lung disease (Golej et al, 2001; Graff et al, 2002; Pollack et al, 1981; Harris & Filandrinos, 1993; Elliot et al, 1989; Rau et al, 1988; Golej et al, 2001; Graff et al, 2002). Refer to the ACTIVATED CHARCOAL/TREATMENT management for further information. 2) Contraindications: unprotected airway (increases risk/severity of aspiration) , nonfunctioning gastrointestinal tract, uncontrolled vomiting, and ingestion of most hydrocarbons (Chyka et al, 2005).
B) WHOLE BOWEL IRRIGATION (WBI) 1) WHOLE BOWEL IRRIGATION may be a relatively safe and effective means of rapid decontamination for the asymptomatic body packer (Olmedo et al, 2001; Betzelos & Mueller, 1991; Hoffman et al, 1990). Activated charcoal should be administered prior to beginning whole bowel irrigation as polyethylene glycol (PEG) solution decreased the ability of charcoal to adsorb drug in vitro (Makosiej et al, 1993). 2) In vitro, cocaine is rapidly hydrolyzed to benzoylecgonine at a pH above 7.4 (Aks et al, 1992). Polyethylene glycol solutions have a pH of 8 and enhance transit from the stomach to the alkaline small intestine, thus potentially diminishing cocaine absorption from leaking packets. 3) However, as benzoylecgonine is not pharmacologically inactive (Brogan et al, 1992; Kurth et al, 1993), it is not clear what clinical effect the intraintestinal hydrolysis of cocaine would have (Konkol & Olsen, 1993). 4) One study reported that WBI with PEG used to treat contraband body packers had no higher complication frequency than other reported methods. There was no correlation between the mean length of hospital stay and either PEG dose, drug type, packet quantity, or packet weight (Farmer & Chan, 2003). a) WHOLE BOWEL IRRIGATION/INDICATIONS: Whole bowel irrigation with a polyethylene glycol balanced electrolyte solution appears to be a safe means of gastrointestinal decontamination. It is particularly useful when sustained release or enteric coated formulations, substances not adsorbed by activated charcoal, or substances known to form concretions or bezoars are involved in the overdose. 1) Volunteer studies have shown significant decreases in the bioavailability of ingested drugs after whole bowel irrigation (Tenenbein et al, 1987; Kirshenbaum et al, 1989; Smith et al, 1991). There are no controlled clinical trials evaluating the efficacy of whole bowel irrigation in overdose.
b) CONTRAINDICATIONS: This procedure should not be used in patients who are currently or are at risk for rapidly becoming obtunded, comatose, or seizing until the airway is secured by endotracheal intubation. Whole bowel irrigation should not be used in patients with bowel obstruction, bowel perforation, megacolon, ileus, uncontrolled vomiting, significant gastrointestinal bleeding, hemodynamic instability or inability to protect the airway (Tenenbein et al, 1987). c) ADMINISTRATION: Polyethylene glycol balanced electrolyte solution (e.g. Colyte(R), Golytely(R)) is taken orally or by nasogastric tube. The patient should be seated and/or the head of the bed elevated to at least a 45 degree angle (Tenenbein et al, 1987). Optimum dose not established. ADULT: 2 liters initially followed by 1.5 to 2 liters per hour. CHILDREN 6 to 12 years: 1000 milliliters/hour. CHILDREN 9 months to 6 years: 500 milliliters/hour. Continue until rectal effluent is clear and there is no radiographic evidence of toxin in the gastrointestinal tract. d) ADVERSE EFFECTS: Include nausea, vomiting, abdominal cramping, and bloating. Fluid and electrolyte status should be monitored, although severe fluid and electrolyte abnormalities have not been reported, minor electrolyte abnormalities may develop. Prolonged periods of irrigation may produce a mild metabolic acidosis. Patients with compromised airway protection are at risk for aspiration. 6) CASE REPORT - One patient presented with opiate intoxication after swallowing packets wrapped only in electrical tape. He received activated charcoal and polyethylene glycol (PEG) solution and subsequently developed severe opiate intoxication and pulmonary edema. Endoscopy revealed empty packets in the stomach. The authors postulate that PEG may have increased the solubility of the heroin and diminished its adsorption to charcoal (Utecht et al, 1993). C) PROMOTILITY AGENTS 1) Two body packers received promotility agents, erythromycin (250 mg IV ) and metoclopramide (10 mg IV), and successfully passed drug packets. In one body packer, the use of promotility agents resulted in the passage of a packet that had not progressed after 18 hours of WBI therapy. Promotility agents therapy is absolutely contraindicated in patients with gastrointestinal obstruction (Traub et al, 2003a).
D) SURGICAL THERAPY 1) Surgery is probably unnecessary unless the cocaine body packer becomes toxic or has bowel obstruction. Most patients can be managed with whole bowel irrigation, charcoal and observation (Silverberg et al, 2006; Souka, 1999; Caruana et al, 1984; McCarron & Wood, 1983). Intra-abdominal surgery is indicated if bowel obstruction is present or if abdominal radiography shows residual packets remaining in the gastrointestinal tract not removed by WBI (Peake et al, 2009; Queen & Glauser, 2002; Olmedo et al, 2001; Hollander & Hoffman, 2002; Olmedo et al, 1999; Souka, 1999). The clinician should be aware that surgery may fail to detect intraluminal drug packets (Olmedo et al, 2001; McCleave, 1993). 2) According to a retrospective review of 4,660 cocaine body packers detected at the Paris and Frankfurt/Main International Airports from 1985 to 2002, 64 cocaine body packers became symptomatic due to rupture of the packets. Of these 64 symptomatic body packers, 20 underwent emergency surgery with a 100% survival rate and no major complications. The other 44 body packers died before they could be treated (Schaper et al, 2007). 3) Follow-up plain radiography and a barium swallow with small bowel follow-through, or abdominal CT scan should be performed in all patients (Peake et al, 2009; Traub et al, 2003a; Hollander & Hoffman, 2002; Olmedo et al, 2001). 4) Heroin body packers may be initially managed nonsurgically using WBI and continuous-infusion naloxone. Surgery should be performed if the body packer has bowel obstruction (Silverberg et al, 2006; Nelson, 2002; Olmedo et al, 2001).
E) ENDOSCOPY 1) Attempts at endoscopic removal have resulted in spontaneous rupture of packets and this procedure is NOT RECOMMENDED (Peake et al, 2009; Silverberg et al, 2006; Queen & Glauser, 2002; McCleave, 1993; Suarez et al, 1977), although in certain circumstances it may be "cautiously attempted" (Hoffman et al, 1990; Sherman & Zingler, 1990), particularly if the packet will not pass through the pylorus (Peake et al, 2009). The use of fiberoptic gastroduodenoscopy to remove drug-filled packets has produced mixed results (Olmedo et al, 2001).
F) CATHARTICS 1) Although the use of oil-based laxatives is occasionally recommended, they should not be used; these laxatives reduce the tensile strength and "burst" volume of latex products (Traub et al, 2003a). 2) Liquid paraffin or mineral oil may dissolve latex packets and should be avoided (Visser et al, 1998; McCleave, 1993). 3) To avoid possible package rupture or deterioration, gentle laxatives which do not directly stimulate the bowel have been used, but are not routinely recommended (McCleave, 1993). Psyllium, sodium sulfate, and bisacodyl suppositories have been used but are not generally recommended (Queen & Glauser, 2002). 4) Care must be taken not to perforate drug packets which might be in the rectum. 5) CASE SERIES: Utecht et al (1992) presented a series of 14 patients, nine of whom swallowed heroin-containing packets and five of whom inserted them rectally. Thirteen had evidence of packets on KUB. Bisacodyl suppositories were used to evacuate packets from the rectum. No patient received gastric lavage (Utecht et al, 1993).
G) BRONCHOSCOPY 1) Cobaugh et al (1997) reported a successful bronchoscopic removal of a cocaine balloon after aspiration (Cobaugh et al, 1997).
H) ENEMAS/NOT RECOMMENDED 1) Tap water enemas have also resulted in package rupture (Queen & Glauser, 2002; Jonsson et al, 1983); enemas should be avoided (Souka, 1999; McCleave, 1993).
6.5.3) TREATMENT
A) MONITORING OF PATIENT 1) Monitor electrolytes, CBC, CPK, and urinalysis. 2) Perform radiography imaging including plain, barium enhanced abdominal radiographs and/or CT to document packets and removal of packets. 3) Institute continuous cardiac monitoring and obtain serial ECGs. 4) A negative urine drug screen does NOT rule out the possibility of body packing.
|